Genetic diagnosis of a Chinese multiple endocrine neoplasia type 2A family through whole genome sequencing
- PMID: 28569245
- DOI: 10.1007/s12038-017-9686-5
Genetic diagnosis of a Chinese multiple endocrine neoplasia type 2A family through whole genome sequencing
Abstract
Approximately 98% of patients with multiple endocrine neoplasia type 2A (MEN 2A) have an identifiable RET mutation. Prophylactic or early total thyroidectomy or pheochromocytoma/parathyroid removal in patients can be preventative or curative and has become standard management. The general strategy for RET screening on family members at risk is to sequence the most commonly affected exons and, if negative, to extend sequencing to additional exons. However, different families with MEN 2A due to the same RET mutation often have significant variability in the clinical exhibition of disease and aggressiveness of the MTC, which implies additional genetic loci exsit beyond RET coding region. Whole genome sequencing (WGS) greatly expands the breadth of screening from genes associated with a particular disease to the whole genome and, potentially, all the information that the genome contains about diseases or traits. This is presumably due to additive effect of disease modifying factors. In this study, we performed WGS on a typical Chinese MEN 2A proband and identified the pathogenic RET p.C634R mutation. We also identified several neutral variants within RET and pheochromocytoma-related genes. Moreover, we found several interesting structural variants including genetic deletions (RSPO1, OVCH2 and AP3S1, etc.) and fusion transcripts (FSIP1-BAZ2A, etc.).
Similar articles
-
Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).Endocr J. 1995 Aug;42(4):527-36. doi: 10.1507/endocrj.42.527. Endocr J. 1995. PMID: 8556060
-
Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.Fam Cancer. 2016 Jan;15(1):99-104. doi: 10.1007/s10689-015-9828-6. Fam Cancer. 2016. PMID: 26254625
-
Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A.Ann Surg. 1994 Sep;220(3):237-47; discussion 247-50. doi: 10.1097/00000658-199409000-00002. Ann Surg. 1994. PMID: 7916559 Free PMC article.
-
Multiple endocrine neoplasia, the old and the new: a mini review.G Chir. 2012 Nov-Dec;33(11-12):370-3. G Chir. 2012. PMID: 23140918 Review.
-
Multiple endocrine neoplasia type 2.Curr Treat Options Oncol. 2004 Aug;5(4):315-25. doi: 10.1007/s11864-004-0022-6. Curr Treat Options Oncol. 2004. PMID: 15233908 Review.
Cited by
-
Variability in Medullary Thyroid Carcinoma in RET L790F Carriers: A Case Comparison Study of Index Patients.Front Endocrinol (Lausanne). 2020 Apr 28;11:251. doi: 10.3389/fendo.2020.00251. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32411094 Free PMC article.
-
C634Y mutation in RET-induced multiple endocrine neoplasia type 2A: A case report.World J Clin Cases. 2024 May 26;12(15):2627-2635. doi: 10.12998/wjcc.v12.i15.2627. World J Clin Cases. 2024. PMID: 38817239 Free PMC article.
-
5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine.Front Endocrinol (Lausanne). 2020 Sep 18;11:543246. doi: 10.3389/fendo.2020.543246. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33071967 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical